Invitae

Invitae expects that Genosity's software and data management platform will allow it to quickly advance several oncology tests in development.

News items for the in vitro diagnostics industry for the week of March 29, 2021.

Of the 32 companies in the index, 14 firms saw their stock prices increase, while 18 saw their share prices decline.

News items for the in vitro diagnostics industry for the week of Feb. 22, 2021.

The company brought in $279.6 million in revenues for the full year, which exceeded the consensus Wall Street estimate.

Although Oppenheimer raised its price target from $48 to $51 in early January, the investment firm sees "increased risk of underperformance for Invitae shares."

Qualifying children will have free access to Invitae's Comprehensive Deafness Panel, which assesses multiple genes linked to syndromic and non-syndromic deafness.

News items for the in vitro diagnostics industry for the week of Jan. 25, 2021.

The company plans to use the net proceeds for working capital, to improve its platform and tests, as well as to expand internationally and acquire assets. 

The company plans to sell nearly 7.2 million shares of its common stock based on an assumed price of $55.86 per share.